跳至主要内容
临床试验/NCT06776341
NCT06776341招募中不适用

Retrospective and Longitudinal Prospective Natural History Study of GEMIN5-Related Neurodevelopmental Disorder

University of Pittsburgh2 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2025年7月7日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
500
试验地点
2
主要终点
neurodevelopmental outcomes

研究概览

简要总结

This study will include a comprehensive retrospective chart review and a longitudinal prospective observational natural history study to characterize the phenotypic spectrum of GEMIN5-Related Neurodevelopmental Disorder. We aim to define the trajectory of this ultra-rare disease, core clinical features, characteristics at disease onset and diagnosis, neurological symptomatology, and neuroimaging findings over time. In this study, biological specimens (serum) will also be collected in a biorepository for translational research purposes.

详细描述

This study will include individuals across the lifespan with molecularly confirmed GEMIN5 biallelic mutations.

This study will be ongoing indefinitely.

There are three main components to the study as are detailed below:

  1. A retrospective chart review of UPMC medical records and other institutions' medical records, for all patients in the study. Families/patients will provide staff with a signed Release of Information, so that we can obtain a copy of the participants complete medical record which will be requested from previously treating physicians. This may include records from several disciplines, for example neurological and physical exams, neurodevelopmental testing (cognitive, motor, language and daily living skills), growth parameters, results to previous genetic testing, MRI, lab results including lumbar puncture studies, audiologic exam, vision screening, nerve conduction studies, ophthalmologic exam, swallow studies, co-morbidities, and family history.
  2. An observational, longitudinal prospective study of patients seen at the UPMC Center for Neuogenomics (CCNG) clinic. Clinical data obtained as part of a typical CCNG visit include vital signs, measurements (weight, head circumference, length), a developmental history, neurodevelopmental testing (eg. cognitive, speech and language, motor skills, developmental skills, vision, hearing), and a comprehensive neurological exam, including an ataxia rating scale. Additionally, any neurodiagnostic results obtained clinically are reviewed if available, such as MRI brain and spine, EEG, and nerve conductions studies.
  3. Patients who are seen at the CCNG clinic in person may opt to submit an optional research biological samples.

Primary endpoint:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

性别
All
接受健康志愿者

入选标准

  • Individuals with molecularly confirmed GEMIN5 biallelic mutations, ages 0 years and above

排除标准

  • 未提供

结局指标

主要结局

neurodevelopmental outcomes

时间窗: 26 years

time to acquisition and/or loss of milestones

次要结局

  • MRI(26 years)
  • Survival(26 years)
  • Hearing(26 years)
  • Biomarkers of disease(26 years)
  • Vision(26 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kate Kielty

Principal Investigator

University of Pittsburgh

研究点 (2)

Loading locations...

相似试验